NicSnap1 inhibitors are a class of chemical compounds that interact with the NicSnap1 protein, a crucial component in cellular signaling pathways. These inhibitors are known for their ability to modulate specific biochemical interactions by selectively binding to the NicSnap1 protein, leading to a reduction in its activity. This modulation affects downstream pathways associated with various intracellular processes, including protein synthesis, cellular stress responses, and energy metabolism. The molecular structure of NicSnap1 inhibitors typically includes diverse chemical scaffolds that allow for a high degree of specificity in targeting NicSnap1. These compounds are designed to maintain strong binding affinity to the NicSnap1 active site, which is often facilitated by hydrophobic interactions, hydrogen bonding, and van der Waals forces, depending on the specific inhibitor's architecture.
NicSnap1 inhibitors can exhibit varied physicochemical properties, such as differing solubility, stability, and permeability, which can be fine-tuned during the development process. Researchers often investigate these properties to ensure the inhibitors perform well in controlled laboratory environments, particularly in experiments involving biochemical assays and protein interaction studies. The development of NicSnap1 inhibitors typically focuses on optimizing key parameters such as binding selectivity and minimization of off-target effects to better understand the mechanistic pathways of NicSnap1. Their distinct molecular makeup provides an important tool for studying the functional role of NicSnap1 in various biological processes, enabling detailed investigations into the protein's structural and functional dynamics in cellular systems.
| Nombre del producto | NÚMERO DE CAS # | Número de catálogo | Cantidad | Precio | MENCIONES | Clasificación |
|---|---|---|---|---|---|---|
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $96.00 $250.00 $750.00 $1428.00 | 280 | |
Inhibe la V-ATPasa, lo que puede afectar al tráfico de vesículas y a la liberación de neurotransmisores. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $260.00 $799.00 | 36 | |
Altera la polimerización de la actina, lo que posiblemente influye en la dinámica de las vesículas sinápticas y en la integridad de las neuronas. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
inhibidor de PI3K, podría afectar a las vías de señalización implicadas en la supervivencia celular y la función sináptica. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $97.00 $254.00 | 36 | |
Inhibe la síntesis de proteínas, lo que puede afectar a la función neuronal y a la plasticidad sináptica. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $178.00 | 25 | |
Inhibe la CaMKII, influyendo posiblemente en la señalización del calcio y la fuerza sináptica. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
inhibidor de MEK, podría afectar a la vía MAPK/ERK implicada en la plasticidad sináptica y la formación de memoria. | ||||||
FK-506 | 104987-11-3 | sc-24649 sc-24649A | 5 mg 10 mg | $76.00 $148.00 | 9 | |
Inhibe la calcineurina, lo que podría influir en la activación de las células T y la neuroinflamación. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Inhibe la PI3K, podría afectar a varias vías de señalización implicadas en el crecimiento y la supervivencia celular. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Inhibidor de la calcineurina, podría modular la respuesta inmunitaria y la neuroprotección. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
inhibidor de la p38 MAPK, podría influir en las respuestas inflamatorias y las vías de estrés celular. | ||||||